Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson L Michael

Showing results (231-240 of 372) with videos related to

Pageof 38
Sort By:
AIDS Research and Human Retroviruses|August 4, 2015
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine RegimensNicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, et al.
Plos Pathogens|March 18, 2022
HIV-1 infections with multiple founders associate with the development of neutralization breadthEric Lewitus, Samantha M Townsley, Yifan Li, et al.
Plos One|October 29, 2014
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participantsKalpana Dommaraju, Gustavo Kijak, Jonathan M Carlson, et al.
Vaccines|January 21, 2023
Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in <i>E. coli</i> Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched VariantsArasu Balasubramaniyam, Emma Ryan, Dallas Brown, et al.
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 12, 2017
Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue CompartmentsTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
The New England Journal of Medicine|October 22, 2009
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandSupachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2004
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trialScott A Wegner, Mark R Wallace, Naomi E Aronson, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Journal of Virology|June 13, 2014
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramideS Moses Dennison, Kara M Anasti, Frederick H Jaeger, et al.
Pageof 38

Showing results (231-240 of 372) with videos related to

Sort By:
Pageof 38
AIDS Research and Human Retroviruses|August 4, 2015
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine RegimensNicos Karasavvas, Chitraporn Karnasuta, Hathairat Savadsuk, et al.
Plos Pathogens|March 18, 2022
HIV-1 infections with multiple founders associate with the development of neutralization breadthEric Lewitus, Samantha M Townsley, Yifan Li, et al.
Plos One|October 29, 2014
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participantsKalpana Dommaraju, Gustavo Kijak, Jonathan M Carlson, et al.
Vaccines|January 21, 2023
Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in <i>E. coli</i> Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched VariantsArasu Balasubramaniyam, Emma Ryan, Dallas Brown, et al.
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 12, 2017
Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue CompartmentsTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
The New England Journal of Medicine|October 22, 2009
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandSupachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2004
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trialScott A Wegner, Mark R Wallace, Naomi E Aronson, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Journal of Virology|June 13, 2014
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramideS Moses Dennison, Kara M Anasti, Frederick H Jaeger, et al.
Pageof 38